Loading your page…
6 companies in 5 countries
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Every medicine of every company in the group, current ones first.
6 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Sibnayal | Potassium citrate, Hydrogen carbonate | EU (EMA) | Authorised | 2021 |
| SIBNAYALGranulato a rilascio prolungato | Potassium citrate, Idrogenocarbonato | Italy | Authorised | |
| Sibnayal 24 mEq, granulaat met verlengde afgifte in sachetGranulaat met verlengde afgifte | Kalium, Kaliumwaterstofcarbonaat, Potassium citrate | Netherlands | Authorised | 2021 |
| SIBNAYAL 24 MEQ GRANULOS DE LIBERACION PROLONGADA846,58 mg + 1581,56 mg · Granulado de liberación prolongada | Potassium, Potasio bicarbonato | Spain | Authorised | 2023 |
| Sibnayal 8 mEq granulaat met verlengde afgifte in sachetGranulaat met verlengde afgifte | Kalium, Kaliumwaterstofcarbonaat, Potassium citrate | Netherlands | Authorised | 2021 |
| SIBNAYAL 8 MEQ GRANULOS DE LIBERACION PROLONGADA282,19 mg + 527,19 mg · Granulado de liberación prolongada | Potassium, Potasio bicarbonato | Spain | Authorised | 2023 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 2 | 2 | 0 | CompaniesAll medicines |
| Netherlands | 2 | 2 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
| Italy | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of France, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.
